Télécharger le texte intégral

Références
166. Camma C, Bruno S, Di Marco V, Di Bona D, Rumi M, Vinci M, et al. Insulin resistance is associated with
steatosis in nondiabetic patients with genotype 1 chronic hepatitis C. Hepatology. 2006 Jan;43(1):64-71.
167. Liakina V, Speiciene D, Irnius A, Semuchiniene T, Valantinas J. Association of the prevalence and grade of
steatosis in patients with chronic hepatitis C with the host and viral factors. Acta Gastroenterol Belg. 2007
Jul-Sep;70(3):260-6.
168. Serfaty L, Andreani T, Giral P, Carbonell N, Chazouilleres O, Poupon R. Hepatitis C virus induced
hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C. J Hepatol. 2001
Mar;34(3):428-34.
169. Mihm S, Fayyazi A, Hartmann H, Ramadori G. Analysis of histopathological manifestations of chronic
hepatitis C virus infection with respect to virus genotype. Hepatology. 1997 Mar;25(3):735-9.
170. Poynard T, Ratziu V, McHutchison J, Manns M, Goodman Z, Zeuzem S, et al. Effect of treatment with
peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology.
2003 Jul;38(1):75-85.
171. Rubbia-Brandt L, Quadri R, Abid K, Giostra E, Male PJ, Mentha G, et al. Hepatocyte steatosis is a cytopathic
effect of hepatitis C virus genotype 3. J Hepatol. 2000 Jul;33(1):106-15.
172. Castera L, Hezode C, Roudot-Thoraval F, Lonjon I, Zafrani ES, Pawlotsky JM, et al. Effect of antiviral
treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of
hepatitis C virus genotype 3 in steatosis. Gut. 2004 Mar;53(3):420-4.
173. Marks KM, Petrovic LM, Talal AH, Murray MP, Gulick RM, Glesby MJ. Histological findings and clinical
characteristics associated with hepatic steatosis in patients coinfected with HIV and hepatitis C virus. J Infect
Dis. 2005 Dec 1;192(11):1943-9.
174. Monto A, Dove LM, Bostrom A, Kakar S, Tien PC, Wright TL. Hepatic steatosis in HIV/hepatitis C
coinfection: prevalence and significance compared with hepatitis C monoinfection. Hepatology. 2005
Aug;42(2):310-6.
175. Sulkowski MS, Mehta SH, Torbenson M, Afdhal NH, Mirel L, Moore RD, et al. Hepatic steatosis and
antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. Aids. 2005 Mar 24;19(6):585-
92.
176. Bani-Sadr F, Carrat F, Bedossa P, Piroth L, Cacoub P, Perronne C, et al. Hepatic steatosis in HIV-HCV
coinfected patients: analysis of risk factors. Aids. 2006 Feb 28;20(4):525-31.
177. McGovern BH, Ditelberg JS, Taylor LE, Gandhi RT, Christopoulos KA, Chapman S, et al. Hepatic steatosis
is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIVseropositive
patients. Clin Infect Dis. 2006 Aug 1;43(3):365-72.
178. Neau D, Winnock M, Castera L, Bail BL, Loko MA, Geraut L, et al. Prevalence of and factors associated with
hepatic steatosis in patients coinfected with hepatitis C virus and HIV: Agence Nationale pour la Recherche
contre le SIDA et les hepatites virales CO3 Aquitaine Cohort. J Acquir Immune Defic Syndr. 2007 Jun
1;45(2):168-73.
179. Sterling RK, Contos MJ, Smith PG, Stravitz RT, Luketic VA, Fuchs M, et al. Steatohepatitis: Risk factors and
impact on disease severity in human immunodeficiency virus/hepatitis C virus coinfection. Hepatology. 2008
Apr;47(4):1118-27.
180. Rodriguez-Torres M, Govindarajan S, Sola R, Clumeck N, Lissen E, Pessoa M, et al. Hepatic steatosis in
HIV/HCV co-infected patients: correlates, efficacy and outcomes of anti-HCV therapy: a paired liver biopsy
study. J Hepatol. 2008 May;48(5):756-64.
181. Verma S, Goldin RD, Main J. Hepatic steatosis in patients with HIV-Hepatitis C Virus coinfection: is it
associated with antiretroviral therapy and more advanced hepatic fibrosis BMC Res Notes. 2008;1:46.
182. Halfon P, Penaranda G, Carrat F, Bedossa P, Bourliere M, Ouzan D, et al. Influence of insulin resistance on
hepatic fibrosis and steatosis in hepatitis C virus (HCV) mono-infected compared with HIV-HCV co-infected
patients. Aliment Pharmacol Ther. 2009 Jul;30(1):61-70.
183. Hourigan LF, Macdonald GA, Purdie D, Whitehall VH, Shorthouse C, Clouston A, et al. Fibrosis in chronic
hepatitis C correlates significantly with body mass index and steatosis. Hepatology. 1999 Apr;29(4):1215-9.
184. Westin J, Nordlinder H, Lagging M, Norkrans G, Wejstal R. Steatosis accelerates fibrosis development over
time in hepatitis C virus genotype 3 infected patients. J Hepatol. 2002 Dec;37(6):837-42.
185. Harrison SA, Brunt EM, Qazi RA, Oliver DA, Neuschwander-Tetri BA, Di Bisceglie AM, et al. Effect of
significant histologic steatosis or steatohepatitis on response to antiviral therapy in patients with chronic
hepatitis C. Clin Gastroenterol Hepatol. 2005 Jun;3(6):604-9.
186. Soresi M, Tripi S, Franco V, Giannitrapani L, Alessandri A, Rappa F, et al. Impact of liver steatosis on the
antiviral response in the hepatitis C virus-associated chronic hepatitis. Liver Int. 2006 Nov;26(9):1119-25.
187. Cacoub P, Carrat F, Bedossa P, Lambert J, Penaranda G, Pol S, et al. Insulin resistance impairs sustained
virological response rate to pegylated interferon plus ribavirin in HIV-hepatitis C virus-coinfected patients:
HOMAVIC-ANRS HC02 Study. Antivir Ther. 2009;14(6):839-45.
188. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR
Cooperative Study Group. Hepatology. 1996;24:289-93.
184